Show simple item record

3- year efficacy and safety for liraglitude 3.0mg in adults with obesity/overweight, prediabetes and baseline BMI <35 vs >/=35kg/m2 in the SCALE obesity and and pore diabetes, double-blind, placebo-controlled trial

dc.contributor.authorFasanmade, O
dc.contributor.authorGreenway, F
dc.contributor.authorLe Roux, C.W
dc.contributor.authorMcGowan, B
dc.contributor.authorPi-Sunyer, X
dc.contributor.authorCancino, A.P
dc.date.accessioned2020-07-16T16:21:38Z
dc.date.available2020-07-16T16:21:38Z
dc.date.issued2007-09
dc.identifier.citationFasanmade O, Greenway F, Le Roux CW, McGowan B, Pi-Sunyer X, Cancino AP, Van Gaal L. 3- year efficacy and safety for liraglitude 3.0mg in adults with obesity/overweight, prediabetes and baseline BMI <35 vs >/=35kg/m2 in the SCALE obesity and and pore diabetes, double-blind, placebo-controlled trial. 2017 book of abstracts Endocrinology and Metabolism Society of Nigeria.en_US
dc.identifier.urihttps://ir.unilag.edu.ng/handle/123456789/8632
dc.language.isoen_USen_US
dc.publisherEndocrine and Metabolism Society of Nigeriaen_US
dc.subjectLiraglutide, obesity, efficacyen_US
dc.title3- year efficacy and safety for liraglitude 3.0mg in adults with obesity/overweight, prediabetes and baseline BMI <35 vs >/=35kg/m2 in the SCALE obesity and and pore diabetes, double-blind, placebo-controlled trialen_US
dc.typePresentationen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record